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Abstract
Advancements in sequencing technologies have empowered recent efforts to identify polymorphisms and mutations on a
global scale. The large number of variations and mutations found in these projects requires high-throughput tools to
identify those that are most likely to have an impact on function. Numerous computational tools exist for predicting which
mutations are likely to be functional, but none that specifically attempt to identify mutations that result in hyperactivation
or gain-of-function. Here we present a modified version of the SIFT (Sorting Intolerant from Tolerant) algorithm that utilizes
protein sequence alignments with homologous sequences to identify functional mutations based on evolutionary fitness.
We show that this bi-directional SIFT (B-SIFT) is capable of identifying experimentally verified activating mutants from
multiple datasets. B-SIFT analysis of large-scale cancer genotyping data identified potential activating mutations, some of
which we have provided detailed structural evidence to support. B-SIFT could prove to be a valuable tool for efforts in
protein engineering as well as in identification of functional mutations in cancer.
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Introduction
The growing amount of mutation and polymorphism data being
generated has created a need for computational tools to
systematically analyze large sets of mutations and filter them for
those that have the greatest potential functional impact. Several sets
of tools have become available that attempt to predict the functional
impact of amino acid substitutions, thus providing a valuable
arsenal for identifying mutations that should be the subject of
further investigations [1–6]. The SIFT (Sorting Intolerant from
Tolerant) algorithm [3], is arguably the most commonly used tool
for detecting deleterious amino acid substitutions due to its easy
application towards large numbers of mutations. However, SIFT
andothertoolslikeitonly attempttodistinguish between two classes
of mutations, often categorized as deleterious and tolerated [3] or
non-neutralandneutral[6].Ithasbeen shown that manyimportant
mutations, in cancer for example, are a result of activating or gain-
of-function mutations. Most current tools do not make an effort to
specifically identify such mutations and distinguish them from
functionally deleterious substitutions. We hypothesize that there are
at least three categories of activating mutations: mutations that
destabilize the inactive form of a molecule thereby resulting in
constitutive activation (e.g. EGFR L858R), mutations that mimic
the activated state (e.g. phosphorylated) of a protein (e.g. BRAF
V600E), and mutations that introduce an evolutionarily more
common residue which enhances proteins activities. Our focus is on
the latter form of activating mutations. These mutations may simply
increase enzymatic activity or substrate binding through more
beneficial biochemical interactions.
Here we present a modified version of SIFT called Bi-
directional SIFT (B-SIFT) which is able to identify both
deleterious and a subset of activating mutations given a protein
sequence and a query mutation within that sequence. The SIFT
algorithm relies upon evolutionary conservation to find mutations
that have the greatest potential for negative functional impact and
B-SIFT uses the same idea to find mutations with increased fitness.
Intuitively, the concept is that mutating from an evolutionarily
uncommon allele to one that is more commonly present in protein
homologues could result in optimized protein activity. Rather than
simply scoring the mutant allele based on the multiple protein
sequence alignment, as SIFT does, B-SIFT calculates scores for
both the mutant allele and the wild-type allele and returns the
difference of these values as the final score, which effectively
measures relative functional activity (Fig. 1A). In contrast to the
two-category scoring that most bioinformatics tools output, B-
SIFT scores can be interpreted with three categories such that low
scores represent a deleterious effect, scores near zero represent a
neutral effect, and high positive scores identify potential activating
mutations.
To quantify B-SIFT’s ability to classify mutations, we have
validated B-SIFT against two protein mutation datasets: a diverse
set of experimentally described mutagenesis experiments as curated
intheSWISS-PROTproteindatabase(MUTAGENfield[7])anda
large set of single amino acid substitution mutants in human DNase
I. We find that high B-SIFT scores can effectively enrich for
activating mutations in both datasets. The DNase I results
demonstrate that B-SIFT could be capable of providing a starting
point in protein engineering efforts by identifying candidate
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structure or functional data (see Results S1 and Figure S1).
Perhaps the most important recent application of mutation
analysis tools is in the realm of cancer research, where an influx of
data regarding somatic mutations found in cancer emphasizes the
need for efficient and reliable analysis methods [8–14]. Because of
the inherent genetic instability of many cancers, it is known that
many mutations found in cancer cells are a result of the cancer
itself (passengers) rather than actual contributors to disease
progression (drivers) [15].We have analyzed a large set of
experimentally discovered cancer-associated somatic mutations
with B-SIFT and performed a detailed structural analysis to
predict the mutations most likely to be activating and potentially
cancer-causing.
Hyperactive or gain-of-function mutations comprise an area of
functional analysis that is often overlooked in large-scale mutation
analyses. B-SIFT presents the first generalized tool for systematic
prediction of potentially activating missense mutations that are a
result of increased protein fitness, thereby identifying potentially
functional mutations that were previously ignored. We show that
B-SIFT can be used for identification of potential activating
mutations while maintaining SIFT’s ability to identify neutral and
deleterious mutations.
Materials and Methods
The original SIFT software (version 2.1.2) was downloaded
from the official SIFT website (http://blocks.fhcrc.org/sift/SIFT.
html). Protein sequences were retrieved from Uniprot for the
siftalign program. Wrapper scripts were written to streamline
protein sequence retrieval, cache alignment results, and enable
batch processing of the input. B-SIFT score can be calculated as
SIFT(mutant)–SIFT(wild-type) where SIFT(mutant) refers to the
SIFT score calculated for the mutant allele and SIFT(wild-type) is
the score calculated for the wild-type allele. According to SIFT
documentation, results that have a median sequence information
of greater than 3.25 are considered low confidence, so these results
have been filtered from our analysis [16,17].
SWISS-PROT mutagenesis data was downloaded and parsed
from SWISS-PROT release 56. The MUTAGEN field from each
protein entrywasparsedoutandmergedintoasinglefile containing
all MUTAGEN entries. Each mutation was labeled as deleterious,
activating, or neutral based on keyword recognition within only the
first two words of the text description to prevent complications with
exceptionally verbose phenotype descriptions. Mutations with
descriptions that did not match any of the given strings were
discarded from further analysis. Activating mutations contained at
least one of: increase, enhance, activat, constitutive acti, restore.
Mutations annotated as having a small or no effect were labeled as
neutral, these were identified with keywords no effect, no change,
normal, mild, minimal effect, minor, small effect, or wild-type.
Deleterious mutations made up the majority of the dataset and also
containedthegreatest number ofkeywords:decrease,inhibit,reduc,
loss, lower, abolish, abrogate, inactive, diminish, disrupt, impair,
eliminate, no activity, prevent, suppress, increases km, increases the
km. Mutations annotated as activating were then investigated by
hand to remove any false positives, such as mutations described as
‘‘Increases substrate binding and reduces catalytic activity’’ or
‘‘Increases electrophoretic mobility of the protein.’’ This resulted in
the removal of 104 out of 512 mutations (,20%). The final dataset
used for analysis included 408 activating, 1932 neutral, and 9736
deleterious mutations. The complete dataset, including B-SIFT
scores and annotations, is available in Supplemental Data.
DNase I mutations were generated by site-directed mutagenesis
and proteins were expressed in HEK293 cells using methods as
previously described [18–20]. The methyl green assay was used to
measure DNA hydrolytic activity of DNase I in the presence of
2m M M g
2+ and 2 mM Ca
2+ as reported previously [20,21].
DNase I concentrations were determined by ELISA, using a goat
anti-DNase I polyclonal antibody coat and detecting with a rabbit
anti-DNase I polyclonal antibody conjugated to horseradish
peroxidase as described previously [20,21]. In both assays,
multiple sample dilutions were compared to standard curves of
wildtype DNase I to determine concentrations. The relative
specific activity (RSA) was calculated by normalizing the specific
activity of the mutant to the specific activity of wild-type DNase I.
Our analyses of DNase I mutations are described in Results S1
and Figure S1.
SNP data was downloaded from NCBI dbSNP database build
126 (http://www.ncbi.nlm.nih.gov/projects/SNP/) [22]. Because
Figure 1. B-SIFT schematic and performance compared to SIFT.
A. Schematic of B-SIFT scoring range versus original SIFT. SIFT generates
scores for each substitution on a scale from 0 to 1, with scores closer to
zero representingthemutationsmostlikelytobedeleterious.B-SIFTisbi-
directional and takes the difference of SIFT scores between the wild-type
and mutant alleles to obtain a score ranging from 21 to 1 with higher
scores representing substitutions more likely to be activating mutations.
B. Performance of B-SIFT versus SIFT in predicting deleterious mutations.
A receiver-operator characteristic (ROC) plot showing the true positive
versus false positive performance rates for B-SIFT (red curve, area under
curve=0.75) and SIFT (black curve, area under curve=0.75) in predicting
which of 4041 mutants of the E. coli LacI repressor gene are likely to have
a deleterious functional impact [27,29].
doi:10.1371/journal.pone.0008311.g001
Finding Activating Mutations
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8311B-SIFT uses an amino acid substitution as input and interpretation
of allele frequencies would be complicated by multi-allelic SNPs,
only bi-allelic missense SNPs were used in this analysis, resulting in
a set of 32261 nonsynonymous SNPs (22,219 with median
sequence information less than or equal to 3.25). Each nonsynon-
ymous SNP was translated into the appropriate amino acid change
for use as input into B-SIFT. Allele frequencies were determined
from the SNPAlleleFreq.bcp file from the dbSNP FTP download
site. The raw data used in our dbSNP analysis is available in
Supplemental Data.
Cancer mutation data was obtained from the Sanger Institute
Catalogue Of Somatic Mutations In Cancer web site (http://
www.sanger.ac.uk/cosmic [23,24]). Public cancer genome muta-
tion data was downloaded from their respective publication sites
[8,9,11,12,14] and run through B-SIFT with protein sequences
corresponding to the given transcript identifiers in each publica-
tion. Mutations chosen for further structural analysis had either B-
SIFT score greater than 0.5 or both a positive B-SIFT score and
cancer-specific overexpression with a one-tailed t-test p-value less
than 0.001. Expression data is extracted from the Gene Logic
database (Gene Logic, Inc., Gaithersburg, MD, USA) and based
on the average expression in cancer samples versus normal
samples for the tissue that the mutation was found in. Expression
differences are calculated as a p-value using a two-sample t-test for
the average expression between cancer samples and normal
samples.
Homology models were built using Modeler 9v4. Models of
Pirh2 A190 and Pirh2 A190V were built from the structure of
Pirh2 RING-H2 domain (PDB code: 2jrj). Interaction model
of Pirh2–UbcH7 was built by superimposing the model of Pirh2
over C-cbl from C-cbl–UbcH7 complex (PDB code: 1fbv).




SIFT was originally validated upon previously published large-
scale mutagenesis experiments [26–29], so we used an identical
dataset to validate whether or not B-SIFT could call deleterious
mutants at a rate similar to that of the original SIFT. The E. coli
LacI repressor mutagenesis dataset contained 4004 mutations with
experimentally measured phenotypes that SIFT used for valida-
tion [16]. SIFT was able to predict deleterious mutations in LacI
at approximately 68% total prediction accuracy rate [27,29]. We
analyzed this same dataset with our implementation of B-SIFT
and, using a Receiver-Operator Characteristic (ROC) curve plot,
we show that B-SIFT and the original SIFT have almost identical
true positive/false positive trade-off rates (Fig. 1B) for detection of
deleterious mutations.
The goal of B-SIFT is to enable prediction of activating
mutations in addition to deleterious mutations that SIFT already
predicts, and so we sought out a large-scale mutagenesis dataset
with experimentally verified phenotypes for use in validation of B-
SIFT’s utility. Ng and Henikoff used LacI, HIV-1 protease, and
bacteriophage T4 lysozyme in validation of SIFT, but none of
these three datasets contains information about activating or gain-
of-function phenotypes [26–29]. To test B-SIFT’s ability to predict
activating mutations, we turned to the SWISS-PROT protein
database, which contains literature-curated entries of experimen-
tally determined phenotypes for directed mutagenesis experiments
across a large number of proteins [7] (SWISS-PROT MUTAGEN
field). We filtered the complete set of mutagenesis data from
SWISS-PROT release 56 for single amino acid substitution
mutations, which resulted in a dataset containing 20787
mutations. Mutations are described with a text description of the
experimentally determined phenotype, but these descriptions do
not adhere to any kind of specific format or controlled vocabulary.
To simplify the analysis, we implemented a simple parsing
algorithm to categorize each mutation description as deleterious,
neutral, activating, or uncategorized. This categorization was done
by looking for specific keywords within the first few words of the
description, and since there is no controlled vocabulary the
accuracy of this categorization approach was validated by random
sampling and manual examination (see Methods).
After the filtering by categorization, we were left with 14993
mutations categorized as either activating, neutral, or deleterious.
These mutations were all analyzed by B-SIFT and filtered by
information content of the SIFT alignment (see Methods),
resulting in 12076 remaining mutations of which 408 (3.4%) are
called activating and 9736 (80.6%) are deleterious. The majority of
mutations scored near -1 in all three sets, but this is consistent with
the fact that the majority of these mutations have SIFT scores
close to zero (Figure S2). Even with the low-value peaks, however,
distributions of B-SIFT scores for each of the three categories show
enrichment at the expected B-SIFT values. For example, the
deleterious mutations are enriched for low B-SIFT scores around -
1, the neutral mutations have a score bump near 0 while the
activating mutations have noticeably more mutations in the
positive score range (Fig. 2A). This data can be seen in another
form by examining the fraction of mutations with a given score
cutoff that are classified as either deleterious, neutral, or activating
(Fig. 2B). From this, we see that although only 3.4% of the total
dataset is activating, 22% of the mutations with a B-SIFT score
greater than 0.5 are activating (Fig. 2B) and in fact there is a
consistent enrichment of activating mutations as B-SIFT scores
increase (Fig. 2C). To show that the additional data used in the B-
SIFT calculation improves performance, we also calculated the
enrichment of activating mutations that would result from
increasing SIFT scores alone. We also observe an enrichment of
activating mutations for high SIFT scores, but B-SIFT performs
substantially better (Fig. 2C). At a B-SIFT score cutoff of 0.5, we
observe a 9% sensitivity towards identifying activating mutations
but a 99% specificity, suggesting that we are able to identify only a
subset of activating mutations but the majority of mutations are
correctly classified as non-activating. There are many possible
ways in which a mutant phenotype may be considered activating,
but based on these results on diverse mutagenesis data we feel
confident that B-SIFT is able to identify at least a subset of
activating mutations that would not otherwise be identified by
SIFT.
We further attempted to validate B-SIFT’s ability to identify
activating mutations through analysis of the Protein Mutant
Database (PMD), a database of literature-curated protein mutants
and phenotypes [30]. Although PMD contained a large number of
mutations with phenotype descriptions and annotations, the
interpretation of these descriptions proved to be more complex
than the similar data contained in SWISS-PROT and the results
were inconclusive. The primary obstacle towards proper utiliza-
tion of these protein mutation databases as benchmarks for B-
SIFT was the difficulty in assigning each phenotype as deleterious,
neutral, or activating. We utilized an ad hoc method for doing
initial categorization in both cases, but after extensive manual
examination of the mutations classified as activating in both
datasets, we found that the SWISS-PROT mutations are more
likely to provide interpretable results. All 1170 mutations initially
classified as activating in the two datasets (626 in SWISS-PROT
and 544 in PMD) were examined by hand to call whether or not
Finding Activating Mutations
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Although there is some subjectivity in this analysis, we found that
,80% of SWISS-PROT and ,64% of PMD mutations were
correctly classified as activating, which typically required mention
of increased enzymatic activity or substrate binding. Due to the
difficulty in systematically categorizing activating mutants in
PMD, our analysis focused instead on the SWISS-PROT mutants.
Comparison with SNAP
SNAP (Screening for Non-Acceptable Polymorphisms) is a
neural-network based computational tool trained on a large set of
mutation data, including PMD data, that performs well in
distinguishing neutral from non-neutral amino acid substitutions
[6]. Since SNAP was trained on data that includes activating
mutations, it specifically categorizes its predictions into two
categories: neutral and non-neutral, where the authors intend
non-neutral to include both deleterious and activating mutations.
We applied SNAP to the same set of SWISS-PROT protein
mutants mentioned above and examined the results on a large-
scale.
SNAP outputs three values for each mutation: a binary call of
neutral or non-neutral, a reliability index (RI), and an expected
accuracy. The reliability index and expected accuracy are quality
scores that are highly correlated, and so we only used the reliability
index scores for quality thresholding. 14813 mutations across 4052
protein sequences received both a B-SIFT score and a SNAP
prediction, and so we focused on these mutations for further
analysis.
SNAP predicted only 1731 (11.3%) of these mutants to be
neutral, so the great majority of mutations were predicted to be
non-neutral. In order to investigate SNAP’s ability to distinguish
activating and neutral mutations, we calculated the percentage of
mutations called neutral for each of the three categories at each
reliability index (Figure S3). We found that neutral and activating
mutations have a very similar distribution of SNAP calls until the
reliability index cutoff is raised to 5 or higher, after which
activating mutations are called non-neutral at a rate more similar
to deleterious mutations. If we consider all predictions, we find
that SNAP calls 74% of all activating mutations as non-neutral.
However, among activating mutations with B-SIFT score greater
than or equal to 0.5, SNAP calls only 26% as non-neutral,
implying that B-SIFT is detecting a distinct subset of activating
mutations.
SNP Analysis
Although the majority of our analysis is focused on mutations,
we sought to ensure that B-SIFT is not simply identifying naturally
occurring alleles in polymorphic positions. To do this, we
leveraged the knowledge of natural human genetic variation in
dbSNP to study the relationship between human population allele
frequencies and functional prediction. We analyzed ,32,000
missense SNPs from dbSNP for both B-SIFT score and allele
frequency, calculating SIFT scores for both the reference allele
and the variant to receive a B-SIFT value. These results were then
filtered by information content of the alignment in the same way as
the SWISS-PROT mutagenesis analysis to result in a list of
,22,000 SNPs. Given that evolution will tend to select against
mutations that provide a fitness disadvantage, we would believe
that the ‘‘wild-type’’ or reference allele should be less likely to be
deleterious than a less common polymorphic allele. However, we
found that in some cases the reference allele is not the most
common allele, and this can confound the B-SIFT results, and so
we proceeded to calculate B-SIFT scores treating the more
common allele as the ‘‘wild-type.’’ We then calculated the average
minor allele frequency (MAF) for SNPs with varying B-SIFT
cutoffs and observed a striking positive correlation (Fig. 3A,
r
2=0.97). In other words, residues that have been selected
throughout the population to be primarily just a single allele (and
therefore have a low minor allele frequency) are more likely to be
deleterious when a different, less preferred allele is present. We
would also expect that, in general, polymorphic positions that are
tolerant of multiple high frequency alleles should be functional
with either allele present. This is confirmed by showing B-SIFT
score distribution for SNPs with different minor allele frequencies
(Fig. 3B). SNPs with a low minor allele frequency (,=2%, Fig. 3B,
red line) are much more likely to be deleterious with that minor
allele, whereas those that have high MAF (.=20%, Fig. 3B, blue
line) are much more likely to be tolerant. The distribution of all B-
SIFT scores among available SNPs reveals a tri-modal distribution
with peaks near 21, 0, and 1 (Fig. 3B, black line). These results
Figure 2. Validation of B-SIFT on protein mutation datasets. A. Distribution of B-SIFT scores for SWISS-PROT mutagenesis data. Density plots
showing the distributions of B-SIFT scores for mutations in the SWISS-PROT mutagenesis dataset classified as deleterious (red curve), neutral (black),
and activating (blue). Legend specifies the number of mutations classified under each functional category. B. Mutation composition of SWISS-PROT
mutagenesis data. Each bar shows the percentage of the total mutations that meet the given B-SIFT cutoffs that are classified as either activating
(blue), neutral (green), or deleterious (red). Values in parentheses show the total number of mutations that met each of the B-SIFT score thresholds. C.
Fold enrichment of activating mutations with increasing score cutoffs. As B-SIFT score cutoff is increased, the percentage of activating mutations with
B-SIFT scores greater than or equal to the cutoff increases as well (red line). A B-SIFT cutoff of 21 represents the complete dataset and each
successive point is the fold enrichment over this baseline. In contrast, the green line shows a similar plot but using increasing SIFT cutoffs starting
from 0. Although simply having a high SIFT score also results in enrichment of activating mutations, B-SIFT significantly improves the enrichment.
doi:10.1371/journal.pone.0008311.g002
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common polymorphism, and so our mutation analyses have been
filtered against known SNPs.
Somatic Mutations in Cancer
The rapidly decreasing price and rising throughput of DNA
sequencing has resulted in several efforts to identify somatic
mutations in cancer in a comprehensive manner [8–14]. It is
known that in many cases, the genetic event that drives
tumorigenesis is a single or sequence of somatic mutations that
results in a cancerous cell. Current cancer genome sequencing
efforts are primarily focused on the protein-coding regions of the
genome and so the majority of identified mutations are in the form
of single-amino acid substitution changes. Numerous methods
have been applied to the mutations discovered in these sequencing
projects in an attempt to identify the causal mutations, but the
majority of this analysis has been based upon methods that can
only identify deleterious mutations [1–5].
We have applied B-SIFT towards functional prediction of over
9000 mutations covering somatic alterations in multiple cancer
types, including breast, colorectal, glioblastoma, pancreatic, and
lung [8–14]. In order to ensure that none of our hits are actually
high frequency polymorphisms, we first checked the list of somatic
mutations against dbSNP and two other fully sequenced human
genomes [31,32]. The data can be separated into two sets; one set
of mutations is extracted from the COSMIC database, which is
filtered for mutations more likely to be causal, and the rest of the
data consists of mutations identified from large-scale sequencing
efforts comparing tumor samples to matched normal samples of
the same individual [23,24]. The COSMIC dataset is presumably
enriched for functionally relevant mutations already whereas the
large-scale somatic mutation discovery datasets should contain a
fair number of ‘‘passenger’’ mutations that are functionally
neutral. B-SIFT score distribution for each of the two sets of
mutations confirms this hypothesis (Fig. 4A). A larger proportion
of COSMIC mutations have very low B-SIFT scores, suggesting
that many COSMIC mutations are functionally deleterious. On
the other hand, the B-SIFT score distribution for somatic
mutations discovered by large-scale sequencing projects has a
noticeable bump near zero, suggesting that there is indeed a larger
portion of these mutations that are not functionally relevant.
A small fraction of these somatic mutations have positive B-
SIFT scores. Based on previous validation results, we speculate
that this group of mutations may be enriched for activating
mutations that have the potential to drive cancer. Table 1 shows a
representative list of mutations with B-SIFT score.0.5 or with
both a moderately high score (.0.2) and additional support from
expression data (Gene Logic) showing that this gene may be
overexpressed in cancer in the tissue that the mutation was found.
The expression requirement attempts to find genes where
additional protein function may be involved in cancer develop-
ment or progression.
Structural Analysis
To gain additional insights into this collection of somatic
mutations in cancer, we evaluated whether some of these
mutations would be consistent with functional activation based
on protein structure analysis. We took the full set of B-SIFT results
for somatic mutations found in high-throughput cancer sequenc-
ing datasets and filtered based on alignment quality, B-SIFT score,
and available expression information (see Methods). The resulting
mutations were then mapped to available protein structures (either
exact structure or by homology) through queries to the Unison
database [33]. A total of seventeen mutations could be mapped to
a protein structure with a sequence identity of 50% or greater,
which we then analyzed for their potential impact on protein
function. We present below our arguments for two of these
potentially activating mutations, with detailed analysis of a third
example in Results S1 and Figures S4 and S5.
One of the somatic mutations with a high B-SIFT is H1047L in
the gene phosphatidylinositol-3 kinase alpha isoform (PIK3CA),
with a score of 0.82. PIK3CA is a well-known oncogene and
Figure 3. B-SIFT analysis of naturally occurring variations in dbSNP. A. Average minor allele frequency is correlated with B-SIFT score in
dbSNP. Scatter plot and linear trendline showing that as B-SIFT score increases, the average minor allele frequency (MAF) for bi-allelic SNPs within
each B-SIFT score range also increases, linear regression r
2=0.97, error bars represent the standard error of the mean at each point. B. Distribution of
B-SIFT scores in dbSNP. Density plots showing the distributions of B-SIFT scores for all bi-allelic polymorphisms in dbSNP (black curve), those with
minor allele frequency (MAF) less than or equal to 2% (red), and those with MAF.=20% (blue). The legend shows the number of SNPs included in
each of the distribution curves.
doi:10.1371/journal.pone.0008311.g003
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the kinase domain [34]. This mutation has been shown to be an
activating mutation both experimentally [35] and computationally
[36]. Histidine-1047 is located close to the activation loop and the
change from histidine to leucine results in loss of interactions with
the activation loop making it more flexible. This increase in
flexibility of the activation loop is presumed to result in increased
substrate interaction thus leading to a gain of function. PIK3CA
H1047L is a validation of B-SIFT’s ability to identify potentially
activating mutations.
The mutation A190V in the gene Pirh2 (p53-induced protein
with RING-H2 domain) also gets a high B-SIFT score of 0.83.
Pirh2 is an E3 Ubiquitin ligase and is known to negatively regulate
levels of p53, a powerful tumor suppressor, in the cell [37].
Because Pirh2 promotes p53 degradation through ubiquitination,
additional activity of Pirh2 will result in loss of p53 activity that
will in turn result in cancer [38]. Alanine-190 is located at the C-
terminal end of the central RING-H2 domain. RING-H2
domains mediate the interaction with the E2 enzyme while
transferring Ubiquitin from the E2 enzyme to the substrate (in this
case, p53). The interaction between the RING-H2 domain and E2
is known to be hydrophobically driven [39]. The RING-H2
domain of Pirh2 contains a shallow hydrophobic patch on its
surface, a feature necessary to facilitate this interaction and shared
by other E3 RING-H2 domains like C-cbl [39]. The structures of
the three domains of Pirh2 were separately solved using NMR
spectroscopy [40]. The structure of the RING-H2 domain has
only been solved from residue 127 to 189, and so coordinates of
Ala 190 were not available due to a flexible linker region between
the RING-H2 domain and the C-terminal domain. We
approached this analysis by building separate structural models
of the Pirh2 RING-H2 domain with alanine and valine at position
190 using Modeler [41]. We then built an interaction model of
Pirh2–UbcH7 using the coordinates of the C-cbl-UbcH7 complex.
Figure 4B shows the hydrophobic patch on Pirh2 at the UbcH7
interface (green highlight), the increase in hydrophobicity when
position 190 is mutated from alanine to valine is denoted by the
larger hydrophobic patch (Fig. 4B). Based on previous interaction
studies of RING and HECT E3 ligases with E2 enzymes
[39,42,43], we hypothesize that this increase in hydrophobicity
could result in an increase in binding affinity between the E3 and
E2 proteins that would enhance p53 degradation.
Discussion
We have presented evidence that the bi-directional SIFT
algorithm is capable of finding a subset of mutations that are
potentially functionally activating. This fills an important void in
existing methods for functional analysis of mutations in that there
are no current methods that have been established for identifying
activating or gain-of-function mutations. B-SIFT is not only
capable of filtering for activating mutations, but its accuracy in
identifying deleterious mutations is consistent with that of the
original SIFT algorithm.
There are some caveats to the study of activating mutations
which are independent of the algorithm used, but do apply to B-
SIFT. In particular, in many cases it is difficult to define exactly
what ‘‘hyperactivity’’ means for a given protein. For example, in
the DNase I data that we present, we define activity as DNA
hydrolysis rate. However, there are many factors that can affect
the rate of DNA hydrolysis, including DNA binding, actin binding,
and the actual catalysis of the hydrolysis reaction [19,44,45]. In
most cases, it appears that increasing DNA binding affinity
improves the rate of DNA hydrolysis, but if the enzyme binds
DNA too tightly then overall DNA hydrolysis can become
inhibited by reducing the turnover of new DNA strands on an
individual enzyme molecule.
Perhaps in a more familiar example, there are many examples
of oncogenes in cancer that become tumorigenic as a result of
hyperactivity. Many of these oncogenes are signaling molecules or
receptors that become hyperactive or constitutively active which
can result in uncontrolled cell proliferation [46]. There are many
examples where this misregulated signaling is actually a result of a
loss of function in a regulatory region of a signaling molecule
[46–50]. In these cases, although it is hyperactivation of signaling
that results in oncogenesis, it is in fact a loss-of-function mutation
Figure 4. B-SIFT and structural analysis of potential activating cancer somatic mutations. A. Distribution of B-SIFT scores in cancer
somatic mutation datasets. Density plots showing the distributions of B-SIFT scores for somatic missense mutations listed in COSMIC (black curve)
[23,24] and those found in large-scale cancer sequencing projects representing a large set of cancers including pancreatic, breast, colorectal cancers,
lung adenocarcinoma, and glioblastoma (red) [8,9,11,12,14]. B. Model of Pirh2 interaction surface. Models of Pirh2 at the UbcH2 binding interface,
green shading represents the hydrophobic surface important in the protein-protein interaction. The left model is for wild-type Pirh2 and the model
on the right shows the increased hydrophobic surface that would result from the A190V mutation, the black circle highlights the change.
doi:10.1371/journal.pone.0008311.g004
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in EGFR is a common mutation in cancer and is classified as an
activating mutation, but its effect is a result of the mutation
destabilizing the inactive conformation of the enzyme and causing
it to fold into an active conformation even in the absence of ligand
[51]. Similarly, it is hypothesized that the common V600E
mutation in the BRAF kinase leads to excessive activation of the
enzyme by mimicking phosphorylation and destabilizing its
inactive conformation [52]. B-SIFT will fail to recognize most of
these as being activating mutations, but it does in fact find many of
these as deleterious mutations instead (EGFR L858R B-
SIFT=21, BRAF V600E B-SIFT=21). Our analysis of
COSMIC mutations and other cancer mutations did not find an
enrichment for high B-SIFT scores in COSMIC (Fig. 4A),
implying that the majority of characterized ‘‘activating’’ cancer
mutations fall into this category of deleterious mutations that result
in functional activation and are thus indistinguishable from other
deleterious mutations by B-SIFT. The complexity involved in
analysis of activating mutations is further demonstrated by the
difficulty in categorizing mutations found in protein databases as
deleterious, neutral, or activating. Without a controlled vocabulary
or a clear definition of what constitutes an activating mutation,
especially in the case of mutations with multiple known
phenotypes, systematic identification will continue to be a
challenge.
Our detailed structural analysis of cancer associated somatic
mutations has found several examples of mutations that could
contribute to cancer progression through different mechanisms, all
with high B-SIFT scores. PIK3CA H1047L is an activating
mutation in a well-studied gene with many known activating
mutations that result in cancer [34,53]. Pirh2 is also a known
oncogene, but an activating mutation in this gene results in cancer
indirectly by excessively degrading the p53 tumor suppressor.
It is apparent from our B-SIFT analysis that the systematic
prediction of activating mutations is more complex than the
analogous prediction of deleterious mutations. One confounding
factor is that it seems as though the majority of possible mutations
will in fact result in loss of function, and so the total sample size of
activating mutations is significantly less. This is consistent with the
SWISS-PROT mutagenesis dataset, in which only 3.4% of
mutations appear to be gain of function mutations. Although
these mutations are not an unbiased random sampling of all
possible mutations, conventional wisdom is that it is much easier to
disrupt protein function than to enhance it in some way, and the
distribution of mutation descriptions supports this (,80%
deleterious). B-SIFT produces scores in a way consistent with
the expectation that many more mutations will be deleterious than
activating. In every dataset examined, the distribution of B-SIFT
scores is shifted towards the negative end (Fig. 4A).
The inherent differences between activating and deleterious
mutations are perhaps the greatest contributing factors towards
the relative inaccuracy in prediction quality between the two
mutation types. We find that the use of a B-SIFT cutoff allows for
enriching a mutation dataset for activating mutations, but there
continues to be a high rate of false negatives and false positives
(Fig. 2B). False positives may result from alleles that are
evolutionarily conserved and potentially provide a fitness advan-
tage to the organism, but do not result in measurable optimized
protein function. False negatives could be a result of the multiple
sequence alignment that B-SIFT (and SIFT) relies upon being
limited in its scope. In the case of activating mutations, if the
mutant residue is not used by any of the homologues used in the B-
SIFT alignment, then the algorithm is unlikely to score the
mutation as activating. However, it is certainly possible that there
exist activating mutations that are not otherwise seen in
homologous protein sequences. On the other end of the spectrum,
since it does seem as though the majority of mutations result in loss
of function, it is likely that false positives result from the somewhat
delicate nature of protein structure and function. Even though
protein homologues may be functional with the mutated residue at
the given position, even subtle differences in protein structure
could result in vast differences in function as a result of the
mutation. Although many caveats exist in the study of activating
mutations, B-SIFT provides a starting point by finding mutations
that would otherwise have been missed or indistinguishable from
the deleterious mutations that comprise the majority of currently
identified functional mutations.
Our analysis of large mutation datasets shows that B-SIFT is
easily scalable in the way that SIFT is, and the distribution of B-
SIFT scores can be used to discover high-level characteristics of
the dataset. Furthermore, studies that are interested in finding
activating mutations would find B-SIFT to be a useful tool in
providing a first step for finding mutations most likely to be
activating. There is still significant improvement that is possible in
Table 1. Possible activating mutations found in cancer
sequencing projects.
Refseq Gene Mutation B-SIFT Tissue*
NM_002208 ITGAE V913I 0.92 Colorectal+
NM_014269 ADAM29 P31L 0.91 Colorectal
NM_015436 PIRH2 A190V 0.83 Pancreatic
NM_006218 PIK3CA H1047L 0.82 Breast
NM_001039029 LRTM2 V320I 0.81 Colorectal
NM_014788 TRIM14 P207L 0.79 GBM+
NM_144773 GPR73L1 M165I 0.66 GBM
NM_007181 MAP4K1 A503S 0.66 Lung+
NM_015078 MCF2L2 R622H 0.65 Colorectal
NM_194251 GPR151 G68R 0.63 Pancreatic
NM_001523 HAS1 V521I 0.61 Pancreatic
NM_000059 BRCA2 P920S 0.60 CGA_GBM+
NM_005883 APC2 G2003S 0.53 Breast
NM_015199 ANKRD28 G651E 0.53 Breast
NM_002578 PAK3 P53T 0.52 Lung
NM_025132 WDR19 L214F 0.51 Colorectal
NM_133493 CD109 Q1007E 0.51 Colorectal
NM_030961 TRIM56 P356S 0.45 GBM+
NM_001569 IRAK1 C307F 0.43 Lung+
NM_003920 TIMELESS Q1008E 0.40 Breast+
NM_001262 CDKN2C M1I 0.33 Lung+
NM_005378 MYCN L402F 0.33 Lung+
NM_020341 PAK7 P76T 0.32 Lung+
NM_020341 PAK7 T397K 0.31 Lung+
NM_001078 VCAM1 G395R 0.24 GBM+
*Tissue refers to the cancer tissue that this particular mutation was found in.
Colorectal and breast are from Wood et al. [14], Pancreatic is from Jones et al.
[11], GBM refers to glioblastoma data from Parsons et al. [12], CGA_GBM is
glioblastoma data from The Cancer Genome Atlas publication [8], and lung
refers to lung adenocarcinoma data from Ding et al. [9].
+in the Tissue column denotes that this gene is significantly overexpressed in
cancer (p,0.01, t-test), compared to normal samples of the same tissue type
(Gene Logic expression data, see Methods).
doi:10.1371/journal.pone.0008311.t001
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B-SIFT provides a valuable starting point for such analyses.
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Found at: doi:10.1371/journal.pone.0008311.s001 (0.07 MB
DOC)
Figure S1 DNase I activity for mutants with positive and
negative B-SIFT scores. Each bar shows the mean relative specific
activity (RSA) for DNase I mutants with positive B-SIFT scores
(left bar), negative scores (right bar), or wild-type controls (middle).
Error bars are the standard error of the mean for each dataset.
Found at: doi:10.1371/journal.pone.0008311.s002 (0.73 MB TIF)
Figure S2 Distribution of Swiss-Prot mutant SIFT scores. SIFT
scores of all Swiss-Prot mutants are shifted towards zero, which
contributes to the large number of small B-SIFT scores among all
mutation sets as shown in Figure 2A.
Found at: doi:10.1371/journal.pone.0008311.s003 (0.49 MB
PDF)
Figure S3 Percentage of Swiss-Prot mutations called as Neutral
by SNAP, as separated by mutation category. Activating and
neutral Swiss-Prot mutations show similar distributions of SNAP
calls until higher Reliability Index cutoffs.
Found at: doi:10.1371/journal.pone.0008311.s004 (0.73 MB TIF)
Figure S4 VCAM-1 gene expression in brain tissues. Boxplots of
VCAM-1 expression show the distribution of expression values
between cancerous and normal brain tissues. VCAM-1 is
significantly overexpressed in cancer compared to normal in the
brain.
Found at: doi:10.1371/journal.pone.0008311.s005 (0.77 MB TIF)
Figure S5 VCAM-1 G395R-VLA4 interaction model. Cartoon
representation of VCAM-1 domains 4 and 5 (orange) shown
bound to VLA4 b1 subunit (translucent surface). G395R and
D352 are shown as sticks. The MIDAS, ADMIDAS and LIMBS
sites are shown in magenta, red, and green spheres respectively.
Known and potential interactions are shown in blue and red
dashed lines. The inset shows a close-up view of these interactions.
Found at: doi:10.1371/journal.pone.0008311.s006 (10.66 MB
PDF)
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